IMAB vs. RENB, SKYE, CTMX, INCR, CRVO, SYRS, RPTX, SGMT, CYBN, and RAPT
Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Renovaro (RENB), Skye Bioscience (SKYE), CytomX Therapeutics (CTMX), InterCure (INCR), CervoMed (CRVO), Syros Pharmaceuticals (SYRS), Repare Therapeutics (RPTX), Sagimet Biosciences (SGMT), Cybin (CYBN), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Renovaro (NASDAQ:RENB) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
Renovaro has higher earnings, but lower revenue than I-Mab.
Renovaro has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Renovaro's return on equity of 0.00% beat I-Mab's return on equity.
I-Mab has a consensus price target of $12.25, indicating a potential upside of 600.00%. Given Renovaro's higher possible upside, analysts plainly believe I-Mab is more favorable than Renovaro.
In the previous week, Renovaro had 4 more articles in the media than I-Mab. MarketBeat recorded 4 mentions for Renovaro and 0 mentions for I-Mab. I-Mab's average media sentiment score of 0.34 beat Renovaro's score of 0.00 indicating that Renovaro is being referred to more favorably in the media.
71.4% of Renovaro shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 21.7% of Renovaro shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
I-Mab received 56 more outperform votes than Renovaro when rated by MarketBeat users.
Summary
I-Mab beats Renovaro on 8 of the 12 factors compared between the two stocks.
Get I-Mab News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
